● Recruiting

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia · Sponsor: M.D. Anderson Cancer Center

PhasePhase 1

Planned participants40

Who can joinAll sexes, 2 Years to 18 Years

Healthy volunteersNo

About this study

To find a recommended dose of ASTX727 (cedazuridine/decitabine) in combination with venetoclax for pediatric patients with relapsed AML.

This description comes directly from the study's public registry record.

Talk to the study team

Amber Gibson, DO · (713) 745-8177 · algibson2@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06191978